How to use the speech recognition tool?

NCT02652780

REVERSE

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation.

Type: Interventional



Status of the trial: Completed

Orphan Drug Recognition: No

Inclusion

  • Opening Date: 2016-02-01
  • Closing Date: 2017-08-01

Criteria

Inclusion: Patients with Leber hereditary optic neuropathy (LHON) carrying the m.11778G>A mitochondrial DNA mutationcarrying the m.11778G>A mitochondrial DNA mutation

Exclusion: Disease duration of more than one year in one or both eyes

More information

Children: Yes

Adults: Yes

Funder Type: industry

HCP: Principal investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Neuro-Ophthalmology Rare Diseases (WG2)

Subscribe to our mailing list

* indicates required

This ERN is supported by: